Further prospective studies are warranted to evaluate the potential of using IGF-1 to reduce insulin resistance and improve metabolic and glycaemic measures in individuals with T2DM and obesity or insulin resistance. Here, IGF1 is linked to obesity due to melanocortin 4 receptor deficiency.